30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Anika Therapeutics Transforms to Hybrid Commercial Model -

Anika Therapeutics reports 3Q19 orthopedic revenue of USD $26.8, +11.1% vs. 3Q18.

  • Anika provided updated 2019 full year revenue guidance in the range of $99.2MM to $100.2MM, representing growth of 6% to 7% over 2018
  • The company has embarked on a five-year strategic plan to achieve leadership in joint preservation and restoration, as well as doubling total revenue
  • As part of their strategic plan, Anika is moving beyond their existing partner-based model of selling osteoarthritis pain management products at office call points, which they estimate to be a $1BB market opportunity; a new hybrid commercial organization will sell joint preservation and restoration products in O.R. settings, estimated by leadership to be a $7BB market
  • Within the third quarter, the company appointed James Loerop to the newly created position of Executive Vice President of Business Development and Strategic Planning, as well as appointing Mira Leiwant to the new position of Vice President of Regulatory Affairs, Quality, and Clinical Affairs; additionally, four regional sales directors were onboarded to manage domestic sales territories
  • In September, the company soft launched the TACTOSET surgically-delivered bone repair product in the U.S. with a full commercial launch planed for December 2019
  • Anika is targeting a rotator cuff therapy as the second launch under their new hybrid commercial model, with an estimated market opportunity of $150MM to $200MM and planned 510(k) submission in late 2020 or early 2021
  • Revenue growth for 3Q19 was driven primarily by MONOVISC and CINGAL, both of which delivered double-digit year over year growth
  • On a sequential quarter basis, domestic end user’s sales price decreased in the high single digits, while year-over-year end user volume increased 6% for ORTHOVISC and 26% for MONOVISCPer Chief Financial Officer Sylvia Cheung, pricing has stabilized compared to 2018, with MONOVISC pricing increasing for three consecutive sequential quarters


ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM).

  3Q19 3Q18 $ Chg % Chg
Orthobiologics $26.8 $24.1 $2.7 11.1%
  9mo 19 9mo 18 $ Chg % Chg
Orthobiologics $75.0 $69.8 $5.2 7.4%


ORTHOWORLD estimates orthopaedic sales by geographic region as follows ($MM).

Geographic Region 3Q19 3Q18 $ Chg % Chg
US $21.1 $19.5 $1.6 8.3%
Ex-US $5.6 $4.6 $1.0 22.8%
   Europe $3.5 $2.9 $0.6 20.3%
   Other $2.1 $1.7 $0.5 26.9%
Grand Total $26.8 $24.1 $2.7 11.1%


Net earnings for all Anika Therapeutics revenue are as follows.

3Q19 Amt % of Sales
Sales $29.6  
   Cost of Sales -$6.0 20.1%
   R & D -$4.2 14.0%
   Selling and Admin -$7.5 25.5%
   Other -$2.8 9.3%
Net Earnings $9.2 31.1%


Sources: Anika Therapeutics; ORTHOWORLD estimates.

Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.